Hôpital Européen Marseille
Marseille, France
Location status: Recruiting
NCT Number: NCT06332573
Onco-sexology as a supportive care for patients treated for cancer is still rarely discussed or even non-existent in 2022. However, it's recommended to integrate the preservation of sexual health throughout the treatment and post-cancer process, given the impact of cancer, treatments and the importance of intimate life for a majority of patients.
Onco-sexology is one of the supportive care services validated by The French National Cancer Institute (INCa). It is also an objective of the 2014-2019 cancer plan and the 2017-2030 national sexual health strategy plan.
Although sexuality is one of the fundamental needs of the human being, including in the case of a chronic disease or cancer diagnosis, the lack of training of health professionals to deal with intimate life, the difficulty to exchange on this subject between caregivers and patients, the lack of financial support for onco-sexology consultations, are all obstacles to the global management of oncology patients. However, it's a request from patients to be able to discuss the subject in an intimate way with a professional.
While onco-sexology is already recommended as supportive care, a study on the impact of the delay in the management of sexual difficulties on quality of life could provide a sufficient level of evidence to change the practices and the care pathway of the oncology patient. Our objective is to study whether early management in onco-sexology has an impact on quality of life compared to late management (ie onco-sexology consultation before vs. after introduction of systemic oncological treatment).
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Marseille, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Initiation of onco-sexology support before the introduction of systemic oncology treatment
Time frame: 4 months
Time frame: 6 and 12 months after the end of onco-sexology support
Time frame: 4 months
Time frame: 6 and 12 months after the end of onco-sexology support
Time frame: 4 months
Time frame: 6 and 12 months after the last consultation with the onco-sexologist
Time frame: 6 and 12 months after the end of onco-sexology support
Time frame: 24 months
Hôpital Européen Marseille
Other
Acronym: SEXOCARE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07724535
Cancer, Neoplasms
Beijing, Beijing Municipality, China
View Trial DetailsNCT05754801
Cancer, Neoplasms
Hong Kong
View Trial DetailsNCT05885048
Cancer, Effects of Immunotherapy
Bern, Switzerland
View Trial DetailsNCT05350761
Cancer, Environment
Bethesda, Maryland, United States
View Trial Details